OakChart

Macrogenics Inc

MGNXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.32-0.10 (-4.13%)
2026-11-12 05:10 CET
Market cap
147.78 USD m
Revenue, TTM
167.67 USD m
Net income, TTM
-14.59 USD m
Free cash flow, TTM
-65.54 USD m
EPS diluted, TTM
-0.23
P/E
-
Compare

Price

MGNX against its 20, 50 and 200-day averages
2050200beatmiss
2.003.004.005.004.8M9.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MGNXclose 2.3220-day 2.6750-day 3.41200-day 3.442.3252w high

54.3% under the 52-week high of 5.08 on 24 Jun 2026. 52-week low 1.32 on 8 Dec 2025. Last 15 sessions, 90.2% high to low

Volume 0.64× normal · the line is the 50-bar volume average

Profile

MGNX
52-week range, 27% of the way up
1.325.08

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

IndexRUT
Employees293
IPOOct 10, 2013
Beta1.32
ATR, 14d0.24
Rel volume0.64
Short float8.06%
Insider own3.54%
Inst own80.49%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap147.78M
Enterprise Value172.72M
Income-14.59M
Sales167.67M
Book/sh0.67
Cash/sh2.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees293
IPOOct 10, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S0.88
P/B3.44
P/C0.85
P/FCF-
EV/EBITDA-
EV/Sales1.03
Quick Ratio2.96
Current Ratio2.96
Debt/Eq4.62
LT Debt/Eq4.51
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.23
EPS next Y-1.64
EPS next Q-0.32
EPS this Y-49.27%
EPS next Y6.89%
EPS next 5Y-20.19%
EPS past 3/5Y15.37% 13.74%
Sales past 3/5Y-0.54% 7.35%
EPS Y/Y TTM59.94%
Sales Y/Y TTM1.32%
EPS Q/Q153.45%
Sales Q/Q47.62%
EarningsNov 04
EPS/Sales Surpr.497.95% -44.48%

Ownership

Insider Own3.54%
Insider Trans-1.36%
Inst Own80.49%
Inst Trans7.49%
ROA-35.12%
ROE-231.86%
ROIC-6.18%
Gross Margin77.86%
Oper. Margin-24.30%
Profit Margin-8.70%
SMA20-13.09%
SMA50-31.96%
SMA200-32.55%
Trades-

Technical

Shs Outstand63.65M
Shs Float61.44M
Short Float8.06%
Short Ratio6.99
Short Interest4.95M
52W High5.08 -54.33%
52W Low1.32 75.76%
Volatility6.17% 10.98%
ATR (14)0.24
RSI (14)34.47
Beta1.32
Rel Volume0.64
Avg Volume707.92K
Volume451,243

Performance

Perf Week0.43%
Perf Month-32.16%
Perf Quarter-43.14%
Perf Half Y-32.75%
Perf YTD44.10%
Perf Year52.63%
Perf 3Y-63.75%
Perf 5Y-88.43%
Perf 10Y-92.19%
Recom2.17
Target Price8.00
Prev Close2.42
Price2.32
Change %-4.13%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Apr 10, 2026UpgradeRB. Riley SecuritiesNeutral → Buy$9+287.9%
Sep 17, 2025ResumedBBarclaysOverweight$3+29.3%
Nov 07, 2024DowngradeJJMP SecuritiesMkt Outperform → Mkt Perform
Aug 01, 2024DowngradeBBTIG ResearchBuy → Neutral
Jul 31, 2024DowngradeGGuggenheimBuy → Neutral
Jul 31, 2024DowngradeRB. Riley SecuritiesBuy → Neutral$18 → $5+115.5%
May 10, 2024DowngradeTTD CowenBuy → Hold
May 10, 2024DowngradeSStifelBuy → Hold$29 → $7+201.7%
May 10, 2024DowngradeBBMO Capital MarketsOutperform → Market Perform$24 → $8+244.8%
Apr 26, 2024InitiatedRB. Riley SecuritiesBuy$25+977.6%

Peers

Mkt cap
TickerCompanyMkt cap
XNCRXencor Inc3.00B
STROSutro Biopharma Inc170.12M
CTMXCytomX Therapeutics Inc464.35M
ZYMEZymeworks BC Inc2.02B
PYXSPyxis Oncology Inc196.16M
CGENCompugen Ltd197.98M
ALXOAlx Oncology Holdings Inc154.87M
IPHAInnate Pharma ADR177.60M
ADAGAdagene Inc ADR143.01M
INBXInhibrx Biosciences Inc1.33B

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Karen FerranteFormer DirectorOct 22 '26Proposed Sale3.6022,00079,204Oct 22 04:16 PM
Bonvini EzioSr VP, Research & CSOOct 06 '26Option Exercise2.608,00020,800193,799Oct 07 04:22 PM
Thomas SpitznagelFormer OfficerSep 21 '26Proposed Sale4.1415,81165,530Sep 21 04:10 PM
Peters Jeffrey StuartSenior VP, GC, and SecretaryAug 19 '26Sale4.1531,105129,0860Aug 20 06:19 PM
Jeffrey PetersOfficerAug 19 '26Proposed Sale4.1531,105129,145Aug 19 05:20 PM
Bonvini EzioSr VP, Research & CSOAug 17 '26Option Exercise2.6040,000104,000185,799Aug 18 04:19 PM
Jay SiegelFormer DirectorAug 17 '26Proposed Sale4.1842,080175,695Aug 17 05:36 PM
Jay SiegelFormer DirectorAug 03 '26Proposed Sale3.7534,916130,935Aug 03 04:30 PM
Thomas SpitznagelFormer OfficerJul 13 '26Proposed Sale4.4417,00075,529Jul 13 09:26 PM
Koenig ScottDirectorFeb 15 '26Option Exercise0.0021,1650867,240Feb 17 06:22 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 200
  • MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors (GlobeNewswire)
  • MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer (GlobeNewswire)
  • MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN (GlobeNewswire) -38.02%
  • MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors (GlobeNewswire)
  • MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • MacroGenics: Q2 Earnings Snapshot (Associated Press)
  • MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position (GlobeNewswire)
  • MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program (GlobeNewswire)
  • MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 (GlobeNewswire) -6.74% -7.73%
  • VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge)
  • MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals (GlobeNewswire)
  • MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval (GlobeNewswire) +10.90%
  • Akari Therapeutics Highlights 1st ASCO Abstract Acceptance (IPO-Edge.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-130.310-0.0780.31032.8359.147
2026Q12026-05-13-0.580-0.574-0.58020.7815.247
2025Q42026-03-09-0.230-0.121-0.22441.2334.596
2025Q32025-11-120.270-0.4460.26672.8425.607
2025Q22025-08-14-0.570-0.423-0.57422.2431.676
2025Q12025-05-13-0.650-0.726-0.65213.199.597
2024Q42025-03-20-0.240-0.279-0.24619.3635.718
2024Q32024-11-050.9000.2120.897110.7187.6110
2024Q22024-08-06-0.890-0.661-0.88810.8020.9410
2024Q12024-05-09-0.840-0.643-0.8389.1014.8611
2023Q42024-03-07-0.740-0.154-0.74210.7232.6310
2023Q32023-11-060.280-0.0950.28210.4050.9010
2023Q22023-08-090.920-0.5210.92313.1429.199
2023Q12023-05-09-0.6100.452-0.61524.5096.1910
2022Q42023-03-150.2000.1020.20873.1058.7811
2022Q32022-11-03-0.400-0.384-0.40441.7329.2811

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.160-3.735-3.15764.1950.18
2020FY-2.470-3.198-2.474104.8876.67
2021FY-3.370-3.252-3.37277.4583.89
2022FY-1.950-2.033-1.949151.94150.06
2023FY-0.1500.426-0.14658.7580.88
2024FY-1.070-1.105-1.069149.96166.33
2025FY-1.180-1.094-1.180149.5138.85
2026FY--1.761--109.83
2027FY--1.640--90.61
2028FY--2.049--88.17
2029FY--2.039--89.96
2030FY--1.013--128.04

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2850119.871.5032.66
2026Q4S2026-10-2351319.871.5032.66
2026Q4S2026-08-2851319.871.5032.66
2026Q4S2026-08-1451223.291.5043.70
2026Q4S2026-07-2860026.3310.0043.70
2026Q4S2026-07-2262226.3310.0043.70
2026Q4S2026-06-1852228.5910.0043.70
2026Q4S2026-05-1462226.3310.0043.70
2026Q4S2026-05-0660028.742.8073.04
2026Q4S2026-04-0950032.492.8073.04
2026Q4S2026-03-1040029.992.8073.04
2026Q4S2026-02-2430015.632.8029.10
2026Q4S2026-02-082008.902.8015.00
2026Q4S2025-11-133009.272.8015.00

Estimate history

EPS, annual-0.54-4.189-3.157-2.474-3.372-1.949-0.146-1.069-1.182-0.2304
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.8880.897-0.246-0.652-0.5740.266-0.224-0.580.307
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual157.74260.12164.188104.88377.447151.94158.749149.962149.5167.67
Period201720182019202020212022202320242025TTM
Sales, quarterly10.797110.70819.35313.19222.24172.83941.22720.77532.832
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual36.85942.35348.95956.24561.30761.70162.07162.8263.31963.646
Period201720182019202020212022202320242025MRQ
Shares, quarterly62.72162.76362.8263.0963.20663.25963.31963.5663.646
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue167.67149.50149.9658.75151.9477.45104.8864.1960.12
Cost of Goods Sold Incl. D&A37.1243.1819.8417.8719.2513.91---
Gross Profit130.55106.32130.1240.88132.6963.54---
Selling, General and Administrative Excl. Other171.30179.16240.70209.13254.11266.33223.99229.07222.13
Research and Development134.55140.00169.65156.94195.16203.32181.24183.01190.83
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-40.75-72.84-110.58-168.24-121.42-202.79-131.06-177.19-171.21
Interest Expense16.908.511.111.430.000.000.000.000.00
Unusual Expense0.000.000.00-150.930.000.000.00-20.10-
Net Income Before Taxes-104.53-75.29-66.02-9.06-119.76-202.12-129.74-151.81-171.45
Income Taxes-0.78-0.670.940.000.000.000.000.000.00
Consolidated Net Income-103.75-74.62-66.97-9.06-119.76-202.12-129.74-151.81-171.45
Net Income From Continuing Operations-103.75-74.62-66.97-9.06-119.76-202.12-129.74-151.81-171.45
Net Income-14.59-74.62-66.97-9.06-119.76-202.12-129.74-151.81-171.45
EPS (Recurring)-0.23-1.18-1.07-1.85-1.95-3.37-2.47-3.45-4.19
EPS (Basic, Before Extraordinaries)-0.23-1.18-1.07-0.15-1.95-3.37-2.47-3.16-4.19
EPS (Diluted)-0.23-1.18-1.07-0.15-1.95-3.37-2.47-3.16-4.19
EBITDA-34.86-65.67-103.04-158.60-109.55-191.54-119.10-164.88-162.01
Non-Operating Income (Expense)-46.886.0645.679.691.660.681.325.27-0.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.2711.2923.2618.3720.4423.1320.6819.5716.52
Price To Earnings Ratio---12.06-----
Price To Sales Ratio1.750.681.3610.142.7112.4211.438.158.65
Gross Margin77.8671.1286.7769.5987.3382.04---
Operating Margin-24.30-48.72-73.74-286.38-79.91-261.85-124.96-276.04-284.77
Net Margin-8.70-49.91-44.66-15.42-78.82-260.97-123.70-236.51-285.18
Shares Outstanding63.6563.3262.8262.0761.7061.3156.2448.9642.35
Market Capitalization147.78147.78203.98596.72412.50983.191,284.82532.66536.69

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue32.8320.7741.2372.8422.2413.1919.35110.71
Cost of Goods Sold Incl. D&A0.7111.2211.8213.3810.817.177.543.71
Gross Profit32.129.5629.4159.4611.436.0211.81107.00
Selling, General and Administrative Excl. Other45.9843.0041.5040.8348.1948.6564.6552.81
Research and Development38.0733.2932.2730.9238.8837.9336.8438.71
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-13.85-33.44-12.1018.64-36.76-42.62-52.8454.19
Interest Expense4.404.894.273.340.800.090.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-69.64-36.77-14.9316.82-36.15-41.04-14.4856.31
Income Taxes0.000.00-0.780.000.100.000.940.00
Consolidated Net Income-69.64-36.77-14.1516.82-36.25-41.04-15.4256.31
Net Income From Continuing Operations-69.64-36.77-14.1516.82-36.25-41.04-15.4256.31
Net Income19.52-36.77-14.1516.82-36.25-41.04-15.4256.31
EPS (Recurring)0.31-0.58-0.220.27-0.57-0.65-0.250.90
EPS (Basic, Before Extraordinaries)0.31-0.58-0.220.27-0.57-0.65-0.250.90
EPS (Diluted)0.31-0.58-0.220.27-0.57-0.65-0.250.90
EBITDA-13.14-31.75-10.3920.43-34.85-40.85-50.7856.03
Non-Operating Income (Expense)-51.391.551.441.531.411.6838.362.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.972.652.103.552.924.3911.275.97
Price To Sales Ratio1.751.170.680.830.460.521.361.46
Gross Margin97.8446.0171.3381.6351.3845.6461.0296.65
Operating Margin-42.19-160.96-29.3425.59-165.27-323.10-273.0248.95
Net Margin59.44-177.01-34.3323.09-162.99-311.07-79.6850.86
Shares Outstanding63.6563.5663.3263.2663.2163.0962.8262.76
Market Capitalization147.78183.68101.85106.1976.3480.12203.98206.36

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments189.91201.67229.81154.35243.62272.53215.76232.86305.12
Short Term Receivables13.374.3110.3756.2210.3923.0812.7429.5813.64
Inventories7.910.001.221.454.390.000.000.000.00
Other Current Assets8.7411.519.9510.1621.1716.9811.296.683.53
Total Current Assets219.94217.49251.34222.18279.56312.59239.78269.12322.30
Net Property, Plant & Equipment35.5242.6145.6956.9154.2861.5268.4156.7149.98
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets7.728.908.409.04-----
Other Assets1.391.561.391.381.414.624.306.291.60
Total Assets264.57270.56306.82289.51335.25378.74312.50332.13373.88
Short Term Debt Incl. Current Port. of LT Debt5.184.863.774.734.683.993.020.000.00
Accounts Payable4.795.016.444.9015.508.034.314.002.45
Other Current Liabilities33.1545.6545.8938.9954.4038.6537.8455.9447.30
Total Current Liabilities43.1255.5356.1148.6174.5850.6745.1759.9449.76
Long Term Debt101.5832.6030.2030.1120.7925.2627.550.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities7.728.908.409.04-----
Other Liabilities56.5557.4759.5059.740.266.939.1529.3124.89
Total Liabilities208.97154.50154.21147.5095.6382.8681.8789.2574.64
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity55.59116.06152.61142.01239.62295.88230.63242.88299.24
Total Shareholders Equity55.59116.06152.61142.01239.62295.88230.63242.88299.24
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity55.59116.06152.61142.01239.62295.88230.63242.88299.24
Total Liabilities & Stockholders Equity264.57270.56306.82289.51335.25378.74312.50332.13373.88
Book Value Per Share0.881.852.462.303.915.264.715.738.12
Tangible Book Value Per Share0.881.852.462.303.915.264.715.738.12
Full-Time Employees293341339357427370384364330
Price to Book Ratio3.441.703.083.354.114.352.312.213.69
Return on Assets-27.89-23.20-3.04-38.34-56.62-37.54-47.10-48.57-5.73
Return on Equity-86.95-49.85-6.15-62.76-75.49-49.28-64.12-63.25-6.91
Return on Invested Capital-47.48-45.05-4.95-69.58-77.61-40.40-58.80-70.59-6.56
Quick Ratio4.923.924.464.543.696.175.314.496.48
Current Ratio5.103.924.484.573.756.175.314.496.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.59-74.62-66.97-9.06-119.76-202.12-129.74-151.81-171.45
Depreciation5.897.177.549.6411.8711.2611.9610.858.28
Other Funds (Non Cash)-36.4214.74-10.34-132.1123.7226.7720.4219.5716.52
Funds from Operations-45.12-52.71-69.77-131.52-84.17-164.09-97.37-121.39-146.65
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-18.60-28.331.3953.32-2.7920.26-14.53-12.88-6.58
Cash from Operating Activities-63.72-81.04-68.37-78.20-86.96-143.83-111.90-134.27-153.23
Capital Expenditures-1.82-1.91-3.71-1.76-3.62-6.20-5.91-4.29-24.95
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.010.0140.160.060.000.000.000.00-
Purchase or Sale of Investments-11.27-112.19112.84-78.3874.34-30.41-1.88-75.0781.60
Purchase of Investments-190.02-208.34-77.18-239.68-120.60-231.21-223.75-264.40-132.75
Sale Or Maturity of Investments178.7596.14190.03161.30194.94200.80221.87189.33214.35
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-13.08-114.10149.30-80.0870.72-36.61-7.79-79.3656.64
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.250.133.441.171.66122.78174.34119.97104.99
Repurchase of Common Pref Stock0.000.000.000.000.000.00-2.010.00-0.26
Sale of Common Pref Stock0.250.133.441.171.66122.78176.35119.97105.25
Proceedsfrom Stock Options0.000.000.000.621.08117.82170.46118.66103.26
Issuance or Reduction of Debt, Net-9.670.000.00-0.160.000.000.000.000.00
Change in Long Term Debt-9.670.000.00-0.160.000.000.000.000.00
Issuance of Long Term Debt-9.670.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.160.000.000.000.000.00
Net Financing Active Other Cash Flow69.4569.39-2.48149.350.000.000.000.000.00
Other Financing Activities Uses-0.22-0.29-2.48-0.310.000.000.000.000.00
Cash from Financing Activities60.0269.510.96150.361.66122.78174.34119.97104.99
Net Change in Cash-16.78-125.6281.88-7.93-14.59-57.6654.66-93.668.40
Free Cash Flow-65.54-82.95-72.08-79.97-90.58-150.03-117.80-138.56-178.19
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments173.31154.23189.91146.40176.49154.14
Short Term Receivables144.1710.4313.3769.2312.5310.54
Inventories0.009.507.918.759.289.43
Other Current Assets4.218.378.747.716.657.98
Total Current Assets321.69182.52219.94232.09204.94182.09
Net Property, Plant & Equipment23.5333.9735.5237.2839.0740.99
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets--7.72---
Other Assets0.201.381.391.391.401.49
Total Assets345.41217.87264.57270.76245.42224.56
Short Term Debt Incl. Current Port. of LT Debt4.985.215.185.145.125.37
Accounts Payable3.444.294.795.944.666.62
Other Current Liabilities100.4086.4433.1533.3929.2243.46
Total Current Liabilities108.8195.9443.1244.4739.0055.44
Long Term Debt193.27100.01101.58102.12102.3932.10
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--7.72---
Other Liabilities0.450.7356.5557.1757.4157.91
Total Liabilities302.54196.68208.97203.76198.80145.45
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity42.8721.2055.5967.0046.6279.12
Total Shareholders Equity42.8721.2055.5967.0046.6279.12
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity42.8721.2055.5967.0046.6279.12
Total Liabilities & Stockholders Equity345.41217.87264.57270.76245.42224.56
Book Value Per Share0.670.330.881.060.741.25
Tangible Book Value Per Share0.670.330.881.060.741.25
Full-Time Employees--293---
Price to Book Ratio3.443.291.522.280.960.69
Return on Assets-35.12-31.80-27.89-28.36-16.30-23.61
Return on Equity-231.86-140.27-86.95-81.13-69.71-60.25
Return on Invested Capital8.26-30.34-9.019.95-24.33-36.90
Quick Ratio2.961.804.925.025.023.11
Current Ratio2.961.905.105.225.253.28

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income19.52-36.77-14.1516.82-36.25-41.04
Depreciation0.711.691.711.791.911.77
Other Funds (Non Cash)-43.231.052.333.444.374.60
Funds from Operations-23.01-34.04-10.1222.05-29.98-34.66
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-17.74-1.7753.14-52.24-17.01-12.23
Cash from Operating Activities-40.75-35.8143.02-30.19-46.98-46.89
Capital Expenditures-0.81-0.34-0.24-0.43-0.71-0.53
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.010.000.000.00
Purchase or Sale of Investments28.7745.66-65.76-19.95-36.9210.43
Purchase of Investments-33.13-1.98-88.85-66.06-45.51-7.92
Sale Or Maturity of Investments61.9047.6423.0946.128.5918.35
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities27.9645.32-65.99-20.37-37.649.90
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.170.010.060.000.070.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.170.010.060.000.070.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net60.000.00-69.670.0069.670.00
Change in Long Term Debt60.000.00-69.670.0069.670.00
Issuance of Long Term Debt60.000.00-69.670.0069.670.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.2269.670.000.00-0.28
Other Financing Activities Uses0.00-0.22-0.010.000.00-0.28
Cash from Financing Activities60.17-0.210.060.0069.74-0.28
Net Change in Cash47.399.30-22.91-50.56-14.88-37.27
Free Cash Flow-41.55-36.1642.78-30.61-47.70-47.42

Revenue breakdown

Contract Manufacturing2024: 13.06M 2025: 52.63M
Product2024: 16.43M
Revenue From Collaborative Agreements2024: 119.92M 2025: 87.18M
RevenueFromRoyalityAgreements2024: 561.00K 2025: 9.69M
United States2024: 149.96M 2025: 149.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.06%4.9M61.4M676.48K
2026-10-158.24%5.1M61.4M597.95K
2026-09-3011.46%7.0M61.5M632.75K
2026-09-1511.44%7.0M61.5M837.97K
2026-08-3111.59%7.1M61.5M852.11K
2026-08-1411.81%7.3M61.4M961.94K
2026-07-3111.97%7.3M61.3M1.18M
2026-07-159.28%5.7M61.3M1.14M
2026-06-3010.81%6.6M61.3M1.15M
2026-06-157.81%4.8M61.3M977.69K
2026-05-298.12%5.0M61.3M1.30M
2026-05-157.95%4.9M61.3M1.25M
2026-04-304.77%2.9M61.4M1.01M
2026-04-154.77%2.9M61.4M1.12M
2026-03-316.15%3.8M61.5M1.11M
2026-03-136.47%4.0M61.5M1.39M
2026-02-276.68%4.1M61.2M1.26M
2026-02-136.90%4.2M61.2M1.30M
2026-01-307.14%4.2M58.2M1.34M
2026-01-156.95%4.0M58.2M1.33M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.851.850.0012.6890.000.000.944-0.0100.000
call2.000.050.650.003.5720.000.000.711-0.0210.001
call3.000.000.300.101.5841320.000.180-0.0090.001
call4.000.001.000.202.5963,0230.000.126-0.0110.001
call5.000.000.450.053.2891140.000.107-0.0120.001
call6.000.001.000.103.81727.000.000.097-0.0130.001
call7.000.001.000.004.2420.000.000.090-0.0140.001
call8.000.001.000.004.5980.000.000.085-0.0150.001
put1.000.000.050.004.2420.000.00-0.053-0.0090.000
put2.000.000.250.092.9423340.00-0.289-0.0200.001
put3.000.401.100.854.4171280.00-0.820-0.0080.001
put4.001.202.151.756.0598.000.00-0.874-0.0110.001
put5.002.203.200.007.2880.000.00-0.893-0.0120.001
put6.003.204.200.007.9520.000.00-0.903-0.0130.001
put7.004.205.200.008.4830.000.00-0.910-0.0130.001
put8.005.106.105.788.2060.000.00-0.915-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-033Initial statement of beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-033Initial statement of beneficial ownership of securities2026-10-30SEC
2026-11-038-KCurrent report2026-10-30SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-22144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-038-K/A2026-09-03SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03SCHEDULE 13G/ASEC
2026-07-29SCHEDULE 13GSEC
2026-07-238-KCurrent report2026-07-23SEC
2026-07-20SCHEDULE 13G/ASEC
2026-07-13144Filing for proposed sale of securities under Rule 144.SEC
2026-07-088-KCurrent report2026-07-01SEC
2026-07-078-KCurrent report2026-06-30SEC
2026-06-05SCHEDULE 13GSEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800129.09K1
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC7.88%
BlackRock, Inc.7.36%
VANGUARD CAPITAL MANAGEMENT LLC4.18%
RENAISSANCE TECHNOLOGIES LLC4.14%
ACADIAN ASSET MANAGEMENT LLC3.99%
BANK OF AMERICA CORP /DE/3.91%
TWO SIGMA INVESTMENTS, LP3.88%
MILLENNIUM MANAGEMENT LLC3.74%
MACKENZIE FINANCIAL CORP3.16%
RA CAPITAL MANAGEMENT, L.P.2.93%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
iShares Russell 2000 ETF2.46%
Wasatch Micro Cap Fund1.21%
Fidelity Small Cap Index Fund1.08%
VANGUARD EXTENDED MARKET INDEX FUND1.02%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.87%
iShares Russell 2000 Growth ETF0.81%
SMALL COMPANY GROWTH PORTFOLIO0.69%
VANGUARD EXPLORER FUND0.66%
Nomura Healthcare Fund0.66%

OakChart. MGNX. Cached 15 minutes.